Humacyte, Inc.

Humacyte, Inc. became a publicly traded company through its business combination with Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC), a blank-check company sponsored by Alpha Healthcare Holdings LLC that completed its IPO in 2021. The SPAC targeted the healthcare and biotechnology sector, and the de-SPAC transaction closed in September 2021, with the combined company subsequently trading on Nasdaq under the ticker HUMA. Humacyte is focused on regenerative medicine, developing bioengineered human acellular vessels for use in vascular surgery and other clinical applications. The June 2024 8-K filing is one of several ongoing periodic disclosures by the post-combination company. Visit SpacDesk and sign up for full access to Humacyte's complete filing history, SPAC deal metrics, and sponsor data.